These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19607942)

  • 1. Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents.
    Gong F; Cheng X; Wang S; Zhao Y; Gao Y; Cai H
    Acta Biomater; 2010 Feb; 6(2):534-46. PubMed ID: 19607942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer.
    Lee YK; Hyung Park J; Tae Moon H; Yun Lee D; Han Yun J; Byun Y
    Biomaterials; 2007 Mar; 28(8):1523-30. PubMed ID: 17157376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
    Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
    Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
    Bhargava B; Reddy NK; Karthikeyan G; Raju R; Mishra S; Singh S; Waksman R; Virmani R; Somaraju B
    Catheter Cardiovasc Interv; 2006 May; 67(5):698-702. PubMed ID: 16575925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model.
    Ma G; Ding S; Feng Y; Shen C; Chen L; Chen Z
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):201-5. PubMed ID: 17703137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating.
    Jabara R; Chronos N; Robinson K
    Catheter Cardiovasc Interv; 2008 Aug; 72(2):186-94. PubMed ID: 18651646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model.
    Yang W; Ge J; Liu H; Zhao K; Liu X; Qu X; Li W; Huang Y; Sun A; Zou Y
    Cardiovasc Res; 2006 Dec; 72(3):483-93. PubMed ID: 17020754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
    Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
    Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a polyphosphazene nanocoat in reducing thrombogenicity, in-stent stenosis, and inflammatory response in porcine renal and iliac artery stents.
    Henn C; Satzl S; Christoph P; Kurz P; Radeleff B; Stampfl U; Stampfl S; Berger I; Richter GM
    J Vasc Interv Radiol; 2008 Mar; 19(3):427-37. PubMed ID: 18295704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo performance of a dual drug-eluting stent (DDES).
    Huang Y; Venkatraman SS; Boey FY; Lahti EM; Umashankar PR; Mohanty M; Arumugam S; Khanolkar L; Vaishnav S
    Biomaterials; 2010 May; 31(15):4382-91. PubMed ID: 20189244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term biocompatibility evaluation of a novel polymer-coated stent in a porcine coronary stent model.
    Huang Y; Liu X; Wang L; Li S; Verbeken E; De Scheerder I
    Coron Artery Dis; 2003 Aug; 14(5):401-8. PubMed ID: 12878906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
    Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biocompatibility of tetramethylpyrazine-eluting stents in normal porcine coronary arteries.
    Ma GS; Chen LJ; Chen Z; Ding S; Shen CX; Feng Y
    Biomed Pharmacother; 2008 Feb; 62(2):125-9. PubMed ID: 17764890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.
    Banai S; Gertz SD; Gavish L; Chorny M; Perez LS; Lazarovichi G; Ianculuvich M; Hoffmann M; Orlowski M; Golomb G; Levitzki A
    Cardiovasc Res; 2004 Oct; 64(1):165-71. PubMed ID: 15364624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells.
    Blindt R; Vogt F; Astafieva I; Fach C; Hristov M; Krott N; Seitz B; Kapurniotu A; Kwok C; Dewor M; Bosserhoff AK; Bernhagen J; Hanrath P; Hoffmann R; Weber C
    J Am Coll Cardiol; 2006 May; 47(9):1786-95. PubMed ID: 16682302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
    Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
    Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts.
    Steigerwald K; Merl S; Kastrati A; Wieczorek A; Vorpahl M; Mannhold R; Vogeser M; Hausleiter J; Joner M; Schömig A; Wessely R
    Biomaterials; 2009 Feb; 30(4):632-7. PubMed ID: 18990438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.